{{Rsnum
|rsid=12143842
|Chromosome=1
|position=162064100
|Orientation=plus
|GMAF=0.2429
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 64.3 | 33.9 | 1.8
| HCB | 43.4 | 50.0 | 6.6
| JPT | 41.6 | 44.2 | 14.2
| YRI | 70.5 | 27.4 | 2.1
| ASW | 64.9 | 33.3 | 1.8
| CHB | 43.4 | 50.0 | 6.6
| CHD | 44.0 | 48.6 | 7.3
| GIH | 34.7 | 43.6 | 21.8
| LWK | 84.5 | 13.6 | 1.8
| MEX | 60.3 | 32.8 | 6.9
| MKK | 79.5 | 19.2 | 1.3
| TSI | 52.9 | 39.2 | 7.8
| HapMapRevision=28
}}[[rs12143842]] is a SNP within 100kb of the NOS1AP gene.

A study of participants in the Rotterdam Study, a population-based, prospective cohort study of individuals >/=55 years of age, concluded that each [[rs12143842]](T) allele was associated with a QT-interval duration increase of 4.4-ms (p =4.4x10e-28). This SNP is the most strongly associated with [[QT interval]] of all known to date (at the time of publication). {{PMID|18927126}}

{{PMID Auto GWAS
|PMID=19305408
|Trait=QT interval
|Title=Common variants at ten loci influence QT interval duation in the QTGEN Study
|RiskAllele=T
|Pval=2E-78
|OR=3.15
|ORtxt=[2.81-3.49] msec increase
|OA=1
}}
{{PMID Auto GWAS
|PMID=19305409
|Trait=QT interval
|Title=Common variants at ten loci modulate the QT interval duration in the QTSCD Study
|RiskAllele=T
|Pval=2E-78
|OR=2.88
|ORtxt=[2.43-3.33] ms increase
|OA=1
}}

{{omim
|desc=QT INTERVAL, VARIATION IN
|id=610141
|rsnum=12143842
}}
{{PMID Auto
|PMID=19587794
|Title=Common genetic variation near the phospholamban gene is associated with cardiac repolarisation: meta-analysis of three genome-wide association studies
|OA=1
}}

{{PharmGKB
|RSID=rs12143842
|Name_s=
|Gene_s=NOS1AP
|Feature=
|Evidence=PubMed ID:19305408; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Common variants at ten loci influence QT interval duation in the QTGEN Study. (Initial Sample Size: 13,685 individuals; Replication Sample Size: 15,854 individuals); (Region: 1q23.3; Reported Gene(s): NOS1AP; Risk Allele: rs12143842-T); (p-value= 2E-78).This variant is associated with QT interval.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164739892
}}

{{PMID Auto
|PMID=20722683
|Title=A common variant of NOS1AP is associated with QT interval duration in a Chinese population with Type 2 diabetes
|OA=1
}}

{{PharmGKB
|RSID=rs12143842
|Name_s=
|Gene_s=NOS1AP
|Feature=
|Evidence=PubMed ID:18927126
|Annotation=This common variant is associated with a QT-interval duration increase of 4.4-ms. per additional T-allele (P=4.4x10(-28)). The T-allele frequency is estimated at 24%.
|Drugs=
|Drug Classes=
|Diseases=Long QT Syndrome
|Curation Level=Curated
|PharmGKB Accession ID=PA162356021
}}

{{PharmGKB
|RSID=rs12143842
|Name_s=
|Gene_s=NOS1AP
|Feature=
|Evidence=PubMed ID:19305409; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Common variants at ten loci modulate the QT interval duration in the QTSCD Study. (Initial Sample Size: 15,842 individuals; Replication Sample Size: up to 13,602 individuals); (Region: 1q23.3; Reported Gene(s): NOS1AP; Risk Allele: rs12143842-T); (p-value= 2E-78).This variant is associated with QT interval.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164739907
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12143842
|overall_frequency_n=35
|overall_frequency_d=128
|overall_frequency=0.273438
|n_genomes=26
|n_genomes_annotated=0
|n_haplomes=29
|n_articles=1
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{PMID Auto
|PMID=23166209
|Title=The Impact of Ancestry and Common Genetic Variants on QT Interval in African Americans
|OA=1
}}

{{PMID Auto
|PMID=24096169
|Title=Single nucleotide polymorphisms in arrhythmia genes modify the risk of cardiac events and sudden death in long QT syndrome
}}

{{PMID Auto
|PMID=23092954
|Title=SHAVE: shrinkage estimator measured for multiple visits increases power in GWAS of quantitative traits.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}